1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1.Bargaining Power of Suppliers
4.3.2.Bargaining Power of Buyers
4.3.3.Threat of New Entrants
4.3.4.Threat of Substitutes
4.3.5.Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. URINARY TRACT INFECTION TREATMENT MARKET BY DRUG CLASS
5.1. Introduction
5.2. Penicillin & Combinations
5.2.1.Market Trends and Opportunities
5.2.2.Growth Prospects
5.3. Quinolones
5.3.1.Market Trends and Opportunities
5.3.2.Growth Prospects
5.4. Cephalosporin
5.4.1.Market Trends and Opportunities
5.4.2.Growth Prospects
5.5. Aminoglycoside Antibiotics
5.5.1.Market Trends and Opportunities
5.5.2.Growth Prospects
5.6. Sulphonamides (Sulfamethoxazole, Trimethoprim)
5.6.1.Market Trends and Opportunities
5.6.2.Growth Prospects
5.7. Azoles and Amphotericin B
5.7.1.Market Trends and Opportunities
5.7.2.Growth Prospects
5.8. Tetracycline (Doxycycline)
5.8.1.Market Trends and Opportunities
5.8.2.Growth Prospects
5.9. Nitrofurans (Nitrofurantoin)
5.9.1.Market Trends and Opportunities
5.9.2.Growth Prospects
5.10. Others
5.10.1.Market Trends and Opportunities
5.10.2.Growth Prospects
6. URINARY TRACT INFECTION TREATMENT MARKET BY INDICATION
6.1. Introduction
6.2. Complicated UTI
6.2.1.Market Trends and Opportunities
6.2.2.Growth Prospects
6.3. Uncomplicated UTI
6.3.1.Market Trends and Opportunities
6.3.2.Growth Prospects
7. URINARY TRACT INFECTION TREATMENT MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacies
7.2.1.Market Trends and Opportunities
7.2.2.Growth Prospects
7.3. Gynecology and Urology Clinics
7.3.1.Market Trends and Opportunities
7.3.2.Growth Prospects
7.4. Drug Stores
7.4.1.Market Trends and Opportunities
7.4.2.Growth Prospects
7.5. Retail Pharmacies
7.5.1.Market Trends and Opportunities
7.5.2.Growth Prospects
7.6. Online Drug Stores
7.6.1.Market Trends and Opportunities
7.6.2.Growth Prospects
8. URINARY TRACT INFECTION TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1.By Drug Class
8.2.2.By Indication
8.2.3.By Distribution Channel
8.2.4.By Country
8.2.4.1. United States
8.2.4.1.1. Market Trends and Opportunities
8.2.4.1.2. Growth Prospects
8.2.4.2. Canada
8.2.4.2.1. Market Trends and Opportunities
8.2.4.2.2. Growth Prospects
8.2.4.3. Mexico
8.2.4.3.1. Market Trends and Opportunities
8.2.4.3.2. Growth Prospects
8.3. South America
8.3.1.By Drug Class
8.3.2.By Indication
8.3.3.By Distribution Channel
8.3.4.By Country
8.3.4.1. Brazil
8.3.4.1.1. Market Trends and Opportunities
8.3.4.1.2. Growth Prospects
8.3.4.2. Argentina
8.3.4.2.1. Market Trends and Opportunities
8.3.4.2.2. Growth Prospects
8.3.4.3. Others
8.3.4.3.1. Market Trends and Opportunities
8.3.4.3.2. Growth Prospects
8.4. Europe
8.4.1.By Drug Class
8.4.2.By Indication
8.4.3.By Distribution Channel
8.4.4.By Country
8.4.4.1. United Kingdom
8.4.4.1.1. Market Trends and Opportunities
8.4.4.1.2. Growth Prospects
8.4.4.2. Germany
8.4.4.2.1. Market Trends and Opportunities
8.4.4.2.2. Growth Prospects
8.4.4.3. France
8.4.4.3.1. Market Trends and Opportunities
8.4.4.3.2. Growth Prospects
8.4.4.4. Italy
8.4.4.4.1. Market Trends and Opportunities
8.4.4.4.2. Growth Prospects
8.4.4.5. Spain
8.4.4.5.1. Market Trends and Opportunities
8.4.4.5.2. Growth Prospects
8.4.4.6. Others
8.4.4.6.1. Market Trends and Opportunities
8.4.4.6.2. Growth Prospects
8.5. Middle East and Africa
8.5.1.By Drug Class
8.5.2.By Indication
8.5.3.By Distribution Channel
8.5.4.By Country
8.5.4.1. Saudi Arabia
8.5.4.1.1. Market Trends and Opportunities
8.5.4.1.2. Growth Prospects
8.5.4.2. UAE
8.5.4.2.1. Market Trends and Opportunities
8.5.4.2.2. Growth Prospects
8.5.4.3. Others
8.5.4.3.1. Market Trends and Opportunities
8.5.4.3.2. Growth Prospects
8.6. Asia Pacific
8.6.1.By Drug Class
8.6.2.By Indication
8.6.3.By Distribution Channel
8.6.4.By Country
8.6.4.1. Japan
8.6.4.1.1. Market Trends and Opportunities
8.6.4.1.2. Growth Prospects
8.6.4.2. China
8.6.4.2.1. Market Trends and Opportunities
8.6.4.2.2. Growth Prospects
8.6.4.3. India
8.6.4.3.1. Market Trends and Opportunities
8.6.4.3.2. Growth Prospects
8.6.4.4. South Korea
8.6.4.4.1. Market Trends and Opportunities
8.6.4.4.2. Growth Prospects
8.6.4.5. Taiwan
8.6.4.5.1. Market Trends and Opportunities
8.6.4.5.2. Growth Prospects
8.6.4.6. Thailand
8.6.4.6.1. Market Trends and Opportunities
8.6.4.6.2. Growth Prospects
8.6.4.7. Indonesia
8.6.4.7.1. Market Trends and Opportunities
8.6.4.7.2. Growth Prospects
8.6.4.8. Others
8.6.4.8.1. Market Trends and Opportunities
8.6.4.8.2. Growth Prospects
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Allergan
10.2. Bayer AG
10.3. Pfizer Inc.
10.4. Janssen Global Services LLC
10.5. Lupin Ltd
10.6. Merck & Co. Inc.
10.7. Almirall S.A
10.8. Shionogi & Co. Ltd
10.9. Novartis AG
10.10. Dr. Reddy’s Laboratories Ltd